Calidi Biotherapeutics Inc.

CLDI | AMEX

Price Alert Chart Builder DCF Calculator

$1.11

+$0.01 (+0.91%)

At close: Sep 21, 2026, 3:59 PM ET

$1.06

-$0.05 (-4.50%)

Pre-market: Sep 22, 2026, 9:10 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $512.14K

Enterprise Value $-2.22M

Beta 1.32

Average Volume 286.27K

Shares Outstanding (Diluted) 1.42M

Shares Change YoY 687.48%

Institutional Ownership 19.49%

Exchange AMEX

ISIN US3207035078

Price Performance

Price Change 1M -15.3%

Price Change 3M -55.6%

Price Change 6M -76.2%

Price Change YTD -94.1%

Price Change 1Y -95.7%

Price Change 3Y -100.0%

Price Change 5Y -100.0%

1M CAGR (ann.) -31.5%

1Y CAGR (ann.) -95.6%

5Y CAGR (ann.) N/A

All-Time CAGR -86.3%

Valuation

PE Ratio -0.02

Forward PE N/A

PEG Ratio -0.00

Forward PEG 0.00

PS Ratio N/A

Forward PS N/A

PB Ratio 0.16

P/FCF Ratio -0.03

P/Adj. FCF Ratio -0.03

P/OCF Ratio -0.09

EV/Sales N/A

EV/EBIT 0.13

EV/EBITDA 0.14

EV/FCF 0.12

Earnings Yield -4877.5%

FCF Yield -3476.9%

Adj. FCF Yield -3743.9%

Financial Health

Net Cash $2.73M

Total Debt $1.34M

Cash & Short-Term Investments $4.07M

Total Assets $7.2M

Current Ratio 1.68

Quick Ratio 1.68

Debt / Equity Ratio 0.62

Debt / EBITDA -0.08

Debt / FCF -0.08

OCF / Debt -13.23

Interest Coverage -114.43

Altman Z-Score -36.63

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -7.7%

Returns

Return on Assets -242.6%

Return on Equity -372.9%

Return on Invested Capital -347.1%

Return on Capital Employed -450.0%

Return on Tangible Assets -242.6%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y -100.0%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 118.5%

EPS CAGR 5Y 40.8%

EPS CAGR 10Y N/A

FCF CAGR 3Y 19.6%

FCF CAGR 5Y -18.2%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 2

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Nov 16, 2026

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $5.50

Price Target Upside 395.5%

Cash Flow

Operating Cash Flow $-17.75M

Free Cash Flow $-17.81M

Adj. Free Cash Flow $-19.17M

FCF Per Share -$12.58

OCF Per Share -$12.54

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-426K

Operating Income $-17.85M

EBITDA $-16.06M

Net Income $-17.47M

EPS (Diluted) -$54.14

Revenue / Employee N/A

Profit / Employee $-602.52K

Employees 29